Novo Nordisk Shares Plunge 18% on Grim 2026 Forecast, Signaling End of Uninterrupted Growth
The Danish pharmaceutical giant warns of its first sales decline in years for 2026, citing U.S. pricing pressures and patent expirations, sending shockwaves through investor confidence and highlighting intensifying competition in the lucrative obesity drug market.